Cohorts

Study Overview

The table below provides an overview on the cohort studies included in Adata(Viewer). It displays the number of recruited participants and key information on the respective study design. Additionally, links are provided which facilitate access to the underlying datasets.

Legend

Cohort	Participants	Healthy	MCI Patients	AD Patients	2+ visits	Follow-up Interval	Location	Diagnostic Criteria	Reference	Data Access
A4	6943	6943	0	0	0	~8	USA, Canada, Australia	Amyloid positive, cog. healthy	DOI	Apply
ABVIB	280	not reported	not reported	not reported	227	12	USA	not reported	DOI	Apply
ADIS	75 (prospective)	25 (prospective)	25 (prospective)	25 (prospective)	0	no follow-up	Spain	Amyloid positive	DOI	Apply
ADNI	2249	813	1016	389	1978	6	USA, Canada	NINCDS-ADRDA	DOI	Apply
AIBL	1378	803	134	181	1019	18	Australia	NINCDS-ADRDA	DOI	^*Shared through consortium
ANM	1702	793	397	512	1254	12	Europe	NINCDS-ADRDA	DOI	Apply
ARWIBO	2617	1476	208	281	80	12	Italy	NINCDS-ADRDA	DOI	Apply
DOD-ADNI	458	181	27	0	458	12	USA, Canada	SFVAMC	DOI	Apply
EDSD	474	183	140	151	0	no follow-up	Europe	NINCDS-ADRCA	DOI	Apply
EMIF	1221	386	526	201	0	no follow-up	Europe	NINCDS-ADRDA	DOI	^*Shared through consortium
EPAD	2096	2071	not reported	14	1596	12	Europe	NINCDS-ADRDA	DOI	Apply
I-ADNI	262	2	54	187	0	no follow-up	Italy	NINCDS-ADRDA	DOI	Apply
JADNI	537	151	233	149	518	6	Japan	NINCDS-ADRDA	DOI	Apply
NACC	40858	15894	3649	11761	27657	12	USA	UDS Form D1	DOI	Apply
OASIS	564	400	122	42	168	6	USA	CDR	DOI	Apply
PREVENT-AD	348	348	0	0	334	12	Canada	excluded MCI	DOI	Apply
PharmaCog	147	0	147	0	133	6	Europe	aMCI with low A-beta 42 CSF levels	DOI	Apply
ROSMAP	3626	2514	898	203	3335	12	USA	NINCDS-ADRDA	DOI	Apply
VASCULAR	250	144	106	0	0	no follow-up	USA	excluded AD	DOI	Apply
VITA	606	440	47	0	606	30	Austria	NINCDS-ADRDA	DOI	Apply
WMH-AD	90	19	26	43	0	no follow-up	Austria	NINCDS-ADRDA	DOI	Apply

^*We emailed the consortium directly and they shared a public version of the data with us.

Column	Description
Cohort	Investigated Cohorts
Participants	Total number of study participants
Healthy Controls	Number of healthy participants
MCI Patients	Number of mild cognitive impaired participants
AD Patients	Number of Alzheimer’s disease patients
2+ visits	Number of study participants for whom data is available for at least two time points
Follow-up Interval	Regular time interval between participant visits
Location	Location of study site(s)
Diagnostic Criteria	Employed diagnostic criteria for Alzheimer’s disease
Reference	Reference to the corresponding publication of the study
Data Access	Information on how we got access to the data. If possible a link for access request is provided.

Column	Description
Cohort	Investigated Cohorts
Female %	Proportion of female study participants
Age	25, 50 and 75% quantile of participant age at baseline
Education	25, 50 and 75% quantile of years of education completed by participants age at baseline
APOE e4 %	Proportion of participants with at least one APOE e4 allele
MMSE	25, 50 and 75% quantile of participants Mini Mental State Examination (MMSE) scores at baseline
CDR	25, 50 and 75% quantile of participants Clinical Dementia Rating scale scores at baseline
CDRSB	25, 50 and 75% quantile of participants Clinical Dementia Rating scale sum of boxes scores at baseline
Hippocampus	25, 50 and 75% quantile of participants hippocampus volume at baseline. The quantiles under the ECDF estimated on the respective studies control population is given in parentheses. AIBL volumes were provided as normalized values. NACC values are given as proportion of “abnormal observations”.
A-beta	25, 50 and 75% quantile of participants CSF amyloid beta at baseline. The quantiles under the ECDF estimated on the respective studies control population is given in parentheses. NACC values are given as proportion of “abnormal observations”.
tTau	25, 50 and 75% quantile of participants CSF total Tau at baseline. The quantiles under the ECDF estimated on the respective studies control population is given in parentheses. NACC values are given as proportion of “abnormal observations”.
pTau	25, 50 and 75% quantile of participants CSF phosphorylated Tau at baseline. The quantiles under the ECDF estimated on the respective studies control population is given in parentheses. NACC values are given as proportion of “abnormal observations”.

Study Overview

AData(Viewer)

Landscape

Other